KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

  • Rapidly Growing, Globally Positioned Biopharmaceutical Company
    - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics
     
  • Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder
    - Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity
     
  • Significant Opportunity in Novel Inhaled AAT Undergoing Pivotal Clinical Development
     
  • Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma
     
  • Valuable R&D Pipeline Focused on Various Orphan Indications
     
  • Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How
     
  • Strong Financial Profile with Increasing Profitability

LATEST NEWS

Kamada Reports Financial Results for Second Quarter and First Six Months of 2017

Aug. 1, 2017

Kamada announced financial results for the three and six months ended June 30, 2017.

Kamada Announces Proposed Public Offering of Ordinary Shares

Jul. 28, 2017

Kamada announced that it intends to offer and sell its ordinary shares in an underwritten public offering.

More News

FINANCIAL REPORTS

Q1 / 2017 Financial Report

Jun. 22, 2017

Annual Report 2016

Dec. 31, 2016

Q3 / 2016 Financial Report

Nov. 10, 2016

More Reports

STOCK QUOTE

NASDAQ

KMDA:$4.3
Change:-3.37%
Date & Time:8/18/2017 3:59pm
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Gil Efron
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more